<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>EANM Dosimetry Committee | Theragnostic Imaging</title>
    <link>https://www.theragnostics.no/en/author/eanm-dosimetry-committee/</link>
      <atom:link href="https://www.theragnostics.no/en/author/eanm-dosimetry-committee/index.xml" rel="self" type="application/rss+xml" />
    <description>EANM Dosimetry Committee</description>
    <generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Fri, 06 Mar 2020 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://www.theragnostics.no/media/icon_hu14557955862192370321.png</url>
      <title>EANM Dosimetry Committee</title>
      <link>https://www.theragnostics.no/en/author/eanm-dosimetry-committee/</link>
    </image>
    
    <item>
      <title>EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours</title>
      <link>https://www.theragnostics.no/en/publications/gear-2020-eanm/</link>
      <pubDate>Fri, 06 Mar 2020 00:00:00 +0000</pubDate>
      <guid>https://www.theragnostics.no/en/publications/gear-2020-eanm/</guid>
      <description>&lt;hr&gt;
&lt;p&gt;The purpose of the EANM Dosimetry Committee Series on &amp;quot;Standard Operational Procedures for Dosimetry&amp;quot; (SOP) is to provide advice to scientists and clinicians on how to perform patient-specific absorbed dose assessments. This SOP describes image and data acquisition parameters and dosimetry calculations to determine the absorbed doses delivered to whole-body, tumour and normal organs following a therapeutic administration of &lt;sup&gt;131&lt;/sup&gt;I mIBG for the treatment of neuroblastoma or adult neuroendocrine tumours. Recommendations are based on evidence in recent literature where available and on expert opinion within the community. This SOP is intended to promote standardisation of practice within the community and as such is based on the facilities and expertise that should be available to any centre able to perform specialised treatments with radiopharmaceuticals and patient-specific dosimetry. A clinical example is given to demonstrate the application of the absorbed dose calculations.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma</title>
      <link>https://www.theragnostics.no/en/publications/walrand-2019-re-/</link>
      <pubDate>Sun, 01 Dec 2019 00:00:00 +0000</pubDate>
      <guid>https://www.theragnostics.no/en/publications/walrand-2019-re-/</guid>
      <description>&lt;hr&gt;
&lt;p&gt;No abstract available&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
